Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 856, Issue 1-2, 2007, Pages 57-61

  Huang, Hui Ching ^a   Liu, Chin Hung ^b   Lan, Tsuo Hung ^a,c,d   Hu, Tsung Ming ^a   Chiu, Hsien Jane ^a   Wu, Yu Chun ^a   Tseng, Ying Lung ^b  

^a Yuli Hospital Department of Health Taiwan   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Aripiprazole; Dehydroaripiprazole; Detection; GC MS; Quantification

Indexed keywords

ARIPIPRAZOLE; DEHYDROARIPIPRAZOLE;

BLOOD; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PATIENT TREATMENT;

DRUG PRODUCTS;

ARIPIPRAZOLE; CARTEOLOL; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; ION; TRIFLUOROACETAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLOOD SAMPLING; CALIBRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; GAS CHROMATOGRAPHY; HUMAN; LINEAR SYSTEM; MASS SPECTROMETRY; MENTAL DISEASE; MENTAL PATIENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; STEADY STATE; VALIDATION PROCESS;

ANTIPSYCHOTIC AGENTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MENTAL DISORDERS; PIPERAZINES; QUINOLONES; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 34548140086     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.05.026     Document Type: Article

References (14)

1. Naber D., and Lambert M. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 1213
2. DeLeon A., Patel N.C., and Crismon M.L. Clin. Ther. 26 (2004) 649
3. Winans E. Am. J. Health Syst. Pharm. 60 (2003) 2437
4. Swainston Harrison T., and Perry C.M. Drugs 64 (2004) 1715
5. Davies M.A., Sheffler D.J., and Roth B.L. CNS Drug Rev. 10 (2004) 317
6. Abilify (Aripiprazole): A Treatment Option For Schizophrenia And Bipolar I Disorder. January 2007, http://www.abilify.com.
7. Molden E., Lunde H., Lunder N., and Refsum H. Ther. Drug Monit. 28 (2006) 744
8. Mallikaarjun S., Salazar D.E., and Bramer S.L. J. Clin. Pharmacol. 44 (2004) 179
9. Carstairs S.D., and Williams S.R. J. Emerg. Med. 28 (2005) 311
10. Kubo M., Mizooku Y., Hirao Y., and Osumi T. J. Chromatogr. B 822 (2005) 294
11. Shimokawa Y., Akiyama H., Kashiyama E., Koga T., and Miyamoto G. J. Chromatogr. B 821 (2005) 8
12. Ayotte C., Goudreault D., and Charlebois A. J. Chromatogr. B 687 (1996) 3
13. W. Schänzer, In Drug Abuse Handbook, Karch SB, editor-in-chief. CRC Press, 1998, p. 671.
14. L. Citrome, R. Josiassen, N. Bark, et al. Paper presented at 2003 Collegium Internationale Neuro-Psychopharmacologium Congress. Montreal, Canada; 2002 Jun 23-27.